 |
 |
 |
|
 |
April 14, 2008 : |
AnGes MG, Inc. Launched Naglazyme in Japan |
|
April 7, 2008 : |
Medical Use Patent on NF-κB Decoy-Oligo Granted in Europe - Covering Its Use for Atopic Dermatitis |
|
March 28, 2008 : |
AnGes Submits NDA for HGF Gene Therapy |
|
March 28, 2008 : |
AnGes MG, Inc. Receives Approval for Manufacturing and Marketing of Naglazyme |
|
February 25, 2008 : |
Status Updates of NDA application of Naglazyme for the Treatment of Mucopolysaccharidosis VI |
|
February 12, 2008 : |
Supplemental Announcement of Results of Phase II Clinical Trials of NF-κB Decoy Oligodeoxinucleotides on Atopic Dermatitis |
|
February 8, 2008 : |
Announcement of Results of Phase II Clinical Trials of
NF-κB Decoy Oligodeoxynucleotide on Atopic Dermatitis |
|
November 13, 2007 : |
AnGes MG, Inc., Signs Licensing Deal with Meyer Pharmaceuticals, LLC - The Development and Marketing of NF-κB Decoy Oligo in North America and Europe- |
|
October 29, 2007 : |
Academic Release of Data from Phase III Clinical Trial of HGF Gene Therapy Conducted in Japan |
|
August 31, 2007 : |
A Research-and-Development Project of GenomIdea Inc.,
a Subsidiary of AnGes MG, Inc. is Granted Subsidy from New Energy and Industrial Technology Development Organization - Development of Cancer Therapeutic Agent Using HVJ-E Vector - |
|
August 29, 2007 : |
Basic Patent of HGF Gene Therapy is Granted in Korea |
|
August 13, 2007 : |
AnGes MG, Inc. Submits BLA for Naglazyme in Japan |
|
July 11, 2007 : |
Basic Patent for HVJ-E Granted in Japan: A Patent Covering HVJ-E Vector (Product Patent) |
| |
|
|
|
|
|
